RxDoctor Payments Data

George Zlupko, MD

Emergency Medicine · Wilmington, DENPI 1548249444

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Among emergency medicine clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$806in general payments, 2019–2025

Across 40 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$124
  • Boehringer Ingelheim$92
  • AbbVie$89
  • Eisai Inc.$81
  • Bsn Medical Inc$56
  • Organogenesis Inc.$50
  • plus $314 from 12 others

What the payments were for

  • Food & beverage$806100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$806 in reported general payments places this provider in the 90th percentile of 189 emergency medicine providers in Delaware.

See all emergency medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$22,190
Medicare patients
99
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.18$22,147
Gentamicin Sulfate28$1,252
Cephalexin34$934
Azithromycin22$104
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$87
Doxycycline Hyclate12$81
Mupirocin12$59
Prednisone14$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$124$22,14718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 189 emergency medicine providers in Delaware.

Other emergency medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →